PDCD1 and metastatic melanoma: A real-world retrospective cohort study investigated the outcome of 185 patients with metastatic melanoma who electively stopped anti-PD-1 therapy with pembrolizumab or nivolumab in the absence of progressive disease or toxicity [53].